However, the E2F targets, Myc targets-v1/v2, interferon alpha and gamma response, G2M checkpoint, mTORC1 signaling, peroxisome, glycolysis and PI3K AKT MTOR signaling pathways were significantly positive correlated to the RiskScore (Figure 6), implying the tremendous heterogeneity existed in varying risk patients mediated by the different cancer activation pathway. This evidence concerns the gene MYC and cancer.